Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tolero Pharmaceuticals
Lehi, Utah, USAtoleropharmaceuticals.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Other
01
Overview
Tolero's lead asset alvocidib (CDK9 inhibitor) completed Phase 2 with improved CR rate (70% vs 46%) in poor-risk AML vs standard care; ongoing Phase 2 in biomarker-positive AML. Other assets in Phase 1 (TP-0903) and preclinical.[3][5]
- Therapeutic areas
- HematologyOncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Sanofi (licensor of alvocidib)
Beyond the preview
Go deeper on Tolero Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tolero Pharmaceuticals.